Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gain Therapeutics, Inc.

< Previous 1 2 Next >
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at Public Ventures Discovery Day
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.